102 completed, 11 recruiting, 10 unknown, 8 withdrawn. 48 Phase 2, 39 Phase 3, 31 Phase 4, 13 Phase 1, 3 Not applicable.
Follow apremilast: new trials by email Literature Review of apremilast trials Research Report on apremilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apremilast and Adalimumab in Psoriatic Arthritis Patients Adalimumab, Apremilast - Psoriatic Arthritis, Ultrasound Assessment | Not applicable | Not yet recruiting | Tanta University | 60 | 2026-12-30 | 2026-09-08 |
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Methotrexate Versus Apremilast for Pruritus in Psoriasis Apremilast, Methotrexate - Psoriasis, Pruritus | Phase 4 | Not yet recruiting | Zarmeen Khawar | 80 | 2026-05-14 | 2026-05-15 |
| Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder Apremilast 60mg, Placebo - Alcohol Use Disorder | Phase 2 | Recruiting | Yale University | 80 | 2026-05-12 | 2026-06-08 |
| Human Laboratory Study of Apremilast for Alcohol Use Disorder Placebo, Apremilast - Alcohol Use Disorder, Alcohol Misuse | Phase 2 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 100 | 2026-04-03 | 2026-05-01 |
| To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital Methotrexate, Apremilast - Chronic Plaque Psoriasis | Early Phase 1 | Recruiting | Syeda Sana Zaman | 106 | 2025-12-25 | 2026-01-13 |
| Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients SFA002, Otezla, Placebo - Psoriasis (PsO) | Phase 2 / Phase 3 | Not yet recruiting | SFA Therapeutics | 125 | 2025-06-01 | 2025-03-11 |
| Adherence to Otezla Otezla - Standard Care, Reminder Text Intervention with apremilast, Extended Consultation for apremilast - Psoriasis | Early Phase 1 | Withdrawn | Wake Forest University Health Sciences | 2025-06-01 | 2025-05-29 | |
| HPP737 in Adult Patients With Plaque Psoriasis HPP737, Placebo matching HPP737, Apremilast - Psoriasis | Phase 3 | Completed | Newsoara Biopharma Co., Ltd. | 607 | 2025-04-18 | 2026-08-03 |
| Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients Apremilast with NB-UVB, NB-UVB - Vitiligo | Phase 4 | Enrolling by invitation | Dow University of Health Sciences | 30 | 2025-01-01 | 2025-03-11 |
| Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis Suppurativa Apremilast, Acitretin - Hidradenitis Suppurativa | Phase 4 | Completed | Hayat Abad Medical Complex, Peshawar | 70 | 2024-12-22 | 2026-07-16 |
| A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Envudeucitinib, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Alumis Inc | 862 | 2024-08-20 | 2026-08-10 |
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Envudeucitinib, Apremilast, Placebo - Plaque Psoriasis | Phase 3 | Completed | Alumis Inc | 912 | 2024-07-25 | 2026-08-10 |
| Apremilast for Alcohol Use Disorder Treatment in Women and Men Apremilast - Alcohol Use Disorder | Phase 1 | Active not recruiting | Yale University | 10 | 2024-05-08 | 2026-02-03 |
| Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus Prednisolone, Apremilast, Methotrexate - Oral Lichen Planus | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 64 | 2024-01-26 | 2025-12-03 |
| A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) Deucravacitinib, Apremilast - Plaque Psoriasis | Recruiting | Bristol-Myers Squibb | 600 | 2024-01-22 | 2024-04-25 | |
| A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) apremilast, Placebo - Plaque Psoriasis | Phase 3 | Completed | Amgen | 203 | 2023-11-27 | 2026-01-05 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment TAK-279, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Takeda | 693 | 2023-11-06 | 2025-10-24 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period TAK-279, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Takeda | 1108 | 2023-11-06 | 2025-11-20 |
Showing 20 of 147. Sign in to see all of them.
Psoriasis (46) · Arthritis, Psoriatic (23) · Arthritis (7) · Dermatitis, Atopic (5) · Pruritus (5) · Alcoholism (4) · Behcet Syndrome (4) · Inflammation (4) · Skin Diseases (4) · Arthritis, Rheumatoid (3) · COVID-19 (3) · Hidradenitis Suppurativa (3) · Vitiligo (3) · Alopecia Areata (2) · Arthritis, Juvenile (2)
Amgen (54) · Bristol-Myers Squibb (5) · Icahn School of Medicine at Mount Sinai (3) · Alumis Inc (2) · Derm Research, PLLC (2) · Kenneth Peters, MD (2) · Oregon Health and Science University (2) · Psoriasis Treatment Center of Central New Jersey (2) · Stanford University (2) · Takeda (2) · Tufts Medical Center (2) · University Hospitals Cleveland Medical Center (2) · University of Erlangen-Nürnberg Medical School (2) · Yale University (2) · AbbVie (1)
United States (89) · Canada (34) · Germany (32) · Spain (24) · France (22) · Italy (19) · United Kingdom (19) · Poland (17) · Czechia (15) · Belgium (14) · Russia (14) · Japan (13) · Australia (12) · Hungary (12) · Israel (11)
Sherry McKee, PhD (2) · Aida Lugo-Somolinos, MD (1) · Alexander Navarini, MD PhD (1) · Alice B. Gottlieb, M.D., PhD. (1) · Alison J Bruce (1) · Andreas Pinter, MD (1) · Andrew G Franks, Jr., MD (1) · Anne Lise Helgesen, MD PhD (1) · Barbara J. Mason, Ph.D. (1) · Boni Elewski, MD (1) · Brian S. Kim, MD (1)
PMID 37316690, PMID 42825996, PMID 30018799, PMID 31077258, PMID 31909868, PMID 34473343, PMID 34536218, PMID 39080153, PMID 39602111, PMID 40113724, PMID 41350512, PMID 42563042, PMID 22508772, PMID 22910104, PMID 22984171, PMID 23588944, PMID 23663752, PMID 23986162, PMID 24595547, PMID 25593233, PMID 25779750, PMID 25875256, PMID 26792812, PMID 27768242, PMID 28899951, PMID 29462231, PMID 29635379, PMID 30528828, PMID 30747550, PMID 31408686, PMID 31722152, PMID 31926340, PMID 32004567, PMID 32267771, PMID 32876697, PMID 33394942, PMID 33509275, PMID 33589554, PMID 33631065, PMID 34077577, PMID 34100922, PMID 34251506, PMID 34255891, PMID 34351721, PMID 34351722, PMID 34606578, PMID 34819613, PMID 34882311, PMID 34977985, PMID 34977986
2018 (7), 2023 (5), 2008 (2), 2014 (2), 2016 (2), 2019 (2), U54AA027989 (2), 2015 (1)